Breaking Down Hubei Zhenhua Chemical Co.,Ltd. Financial Health: Key Insights for Investors

Curious whether Hubei Zhenhua Chemical Co., Ltd. (603067.SS) is a buy, hold or watch? This deep-dive peels back the numbers: quarterly revenue hit 1.03 billion CNY (Q3 2025), with TTM revenue of 4.29 billion CNY and 2024 annual sales of 4.07 billion CNY, while the market currently values the company at roughly 20.29 billion CNY; profitability shows strength with a 15.65% ROE and a first-half 2025 net income attributable to shareholders of 298 million CNY, yet valuation and liquidity metrics - including a trailing P/E of 48.65, forward P/E of 30.52, negative free cash flow (-12.27 million CNY), a net debt position (net cash per share -1.46 CNY) and an EV/EBITDA of 25.32 - underscore key trade-offs for investors, as do a conservative debt-to-equity of 0.38 and an Altman Z-Score of 4.91; read on to explore revenue drivers, profitability margins, leverage, liquidity, valuation nuances and the growth plans such as Phase II of Hubei Xinxuanhong and new product rollouts that could reshape the outlook

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) - Revenue Analysis

Hubei Zhenhua Chemical reported steady top-line growth through recent reporting periods, with momentum visible on both a sequential and year-over-year basis. Key numeric highlights and interpretation are presented below to aid investor assessment.

• Quarter (Q3 ending Sep 30, 2025) revenue: 1.03 billion CNY - up 2.13% sequentially.
• Trailing twelve months (TTM) revenue: 4.29 billion CNY - +8.90% year-over-year.
• Full-year 2024 revenue: 4.07 billion CNY - +9.95% vs. 2023.
• Revenue per employee: ~2.07 million CNY (2,077 employees).
• Price-to-sales (P/S) ratio: 4.73.
• Market capitalization: 20.29 billion CNY.

• Sequential growth in Q3 shows continued demand resilience; TTM and 2024 YoY gains indicate consistent annual expansion.
• Revenue per employee (~2.07M CNY) signals productivity levels relative to peers in the chemical sector (useful for benchmarking).
• With a P/S of 4.73 and market cap of 20.29B CNY, investors should weigh valuation against growth rates and margin profile.

For broader ownership, shareholder trends and investor interest context, see: Exploring Hubei Zhenhua Chemical Co.,Ltd. Investor Profile: Who's Buying and Why?

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) - Profitability Metrics

• Net income attributable to shareholders: 298 million CNY (↑23.62% YoY)
• Gross profit margin: 26.83%
• Operating margin: 14.77%
• Profit margin (net margin): 12.09%
• Return on equity (ROE): 15.65%
• Return on assets (ROA): 7.68%

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) - Debt vs. Equity Structure

• Debt-to-Equity Ratio: 0.38 - conservative leverage, equity base materially larger than debt.
• Interest Coverage Ratio: 16.02 - ample operating income relative to interest expense, low near-term default risk on interest payments.
• Total Debt: 1.33 billion CNY; Net Cash Position: -1.03 billion CNY - company carries net debt (total debt exceeds cash by ~1.03 billion CNY).
• Equity (Book Value): 3.49 billion CNY; Book Value per Share: 4.97 CNY - tangible equity cushion for creditors and shareholders.
• Altman Z-Score: 4.91 - low bankruptcy risk zone, consistent with a financially stable industrial firm.
• Piotroski F-Score: 5 - indicates a middling to stable financial quality with room for operational improvement.

• Investor considerations: the modest leverage (0.38) combined with high interest coverage (16.02) supports financial resilience, while the net debt of 1.03 billion CNY warrants monitoring cash flow generation and working capital management.
• Valuation context: book value per share (4.97 CNY) provides a conservative floor - compare market price to assess margin of safety.

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) - Liquidity and Solvency

Key liquidity and solvency metrics for Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) provide a snapshot of short‑term coverage, cash generation, leverage and overall valuation. Below are the primary figures and their immediate implications.

• Current ratio 2.33: indicates the company has more than twice the current assets needed to meet short‑term liabilities, implying short‑term coverage is comfortable.
• Quick ratio 1.15: shows adequate liquidity even excluding inventory, reducing reliance on slow‑moving stock to meet obligations.
• Working capital 1.45 billion CNY: a positive buffer that supports day‑to‑day operations and seasonal needs.

• Operating cash flow at 207.50 million CNY versus capex 219.76 million CNY: results in a slightly negative free cash flow of -12.27 million CNY, signaling that recent investments marginally exceed cash generated from operations.
• Net cash per share -1.46 CNY: a net debt position on a per‑share basis, which increases financial leverage and interest exposure.
• Enterprise value 21.46 billion CNY: positions the company's total valuation (equity + debt - cash) for comparative analysis versus peers and sector multiples.

For broader investor context and ownership trends, see: Exploring Hubei Zhenhua Chemical Co.,Ltd. Investor Profile: Who's Buying and Why?

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) - Valuation Analysis

Key market valuation metrics for Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) highlight a market pricing that implies expected earnings growth but also signals elevated premium relative to book value and operating cash generation concerns.

• Trailing P/E: 48.65 - reflects recent earnings multiple paid by the market.
• Forward P/E: 30.52 - indicates the market expects improvement in future earnings versus trailing results.
• Price-to-Book (P/B): 5.85 - shows investors are paying a substantial premium over reported book value.
• EV/EBITDA: 25.32 - a relatively high multiple versus typical industrial/chemical peers, implying strong valuation relative to operating cash earnings.
• EV/EBIT: 33.85 - underscores valuation pressure when depreciation/amortization are excluded.
• EV/FCF: -1,749.31 - a very large negative ratio driven by negative free cash flow (FCF), signaling cash-generation weakness or one-off cash items.
• Market Capitalization: 20.41 billion CNY; Enterprise Value: 21.46 billion CNY - small premium from net debt adjustments.

Practical considerations for investors:

• High P/E and P/B suggest investors are pricing significant growth or strategic value; downside risk if growth stalls.
• Elevated EV/EBITDA and EV/EBIT imply less margin for valuation compression in a downturn.
• Negative EV/FCF requires investigation into cash flow drivers - capital expenditure, working capital swings, or one-time charges.
• Compare these multiples to chemical-sector peers and historical-company multiples to assess relative valuation.

For background on the company's history, ownership and how it operates, see: Hubei Zhenhua Chemical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) - Risk Factors

Investors assessing Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) should weigh multiple company-specific and sector-wide risks that could materially affect valuation and downside exposure.

• Market-price pressure: shares hit an intraday low of CNY 17.27 on October 15, 2025, reflecting downside momentum and limited buyer support at those levels.
• High short-term volatility: the stock recorded a 9.32% decline on October 15, 2025, followed by a 10.65% surge on October 22, 2025, underlining rapid sentiment shifts and trading risk.
• Net leverage: reported net cash per share is -1.46 CNY, indicating the company is in a net debt position rather than holding surplus cash to buffer shocks.
• Negative operating liquidity: trailing free cash flow stands at -12.27 million CNY, signalling potential near-term liquidity constraints if losses persist or capex remains elevated.
• Industry and regulatory exposure: operating in the specialty chemicals sector subjects the company to evolving environmental regulations, compliance costs, and potential plant-level restrictions that can affect margins and production.

• Balance-sheet sensitivity: with negative free cash flow and net debt on a per-share basis, the firm is more susceptible to rising interest rates, refinancing risk, or margin compression from raw material price swings.
• Price and sentiment-driven equity risk: large intraday moves indicate potential for sharp unrealized losses for investors and increased cost of capital if equity issuance is required.
• Regulatory and environmental compliance risk: tighter emissions standards, permitting delays or remediation liabilities in the specialty chemicals space can trigger unanticipated expenses and operational curtailments.
• Liquidity and working-capital risk: persistent negative FCF can force asset sales, equity dilution, or increased reliance on short-term borrowing, heightening execution risk for strategic plans.

For historical context on the company's evolution and ownership structure, see Hubei Zhenhua Chemical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) - Growth Opportunities

Hubei Zhenhua Chemical Co.,Ltd. (603067.SS) is positioned to expand capacity, diversify product lines and capture market recovery tailwinds. Key growth drivers and metrics are summarized below.

• Phase II of the Hubei Xinxuanhong Production Plant: construction expected to commence in the second half of 2025.
• New capacity ramp schedule: phased commissioning through 2029, enabling stepwise revenue recognition as units come online.
• Product pipeline: introduction of toluene chlorination products and additional fine chemical products to broaden margins and end-market exposure.
• Macro support: anticipated economic recovery and easing inflation expected to improve topline and margin environment.
• Forward rate of return: 20.25%, signalling attractive expected returns on planned investments.
• Market performance: 114.83% increase over the past year vs. China Shanghai Composite +17.69% for the same period, reflecting strong investor appetite and/or operational momentum.

Operational and strategic milestones to watch:

• H2 2025: ground-breaking for Phase II and major equipment procurement timelines.
• 2026-2029: phased capacity commissioning milestones tied to revenue ramp and margin improvements.
• Product launches: timing and initial volumes for toluene chlorination products and other fine chemicals.
• Macro indicators: GDP growth and CPI trends that affect raw material costs and end-demand.
• Return realization: tracking actual ROI vs. forward rate of return (20.25%).

For broader context on corporate background and how the business operates, see: Hubei Zhenhua Chemical Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money